The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Dose‐Finding Based on Efficacy–Toxicity Trade‐Offs
Abstract
Summary We present an adaptive Bayesian method for dose‐finding in phase I/II clinical trials based on trade‐offs between the probabilities of treatment efficacy and toxicity. The method accommodates either trinary or bivariate binary outcomes, as well as efficacy probabilities that possibly are nonmonotone in dose. Doses are selected for successive patient cohorts based on a set of efficacy–toxicity trade‐off contours that partition the two‐dimensional outcome probability domain. Priors are established by solving for hyperparameters that optimize the fit of the model to elicited mean outcome probabilities. For trinary outcomes, the new algorithm is compared to the method of Thall and Russell(1998,Biometrics54,251–264) by application to a trial of rapid treatment for ischemic stroke. The bivariate binary outcome case is illustrated by a trial of graft‐versus‐host disease treatment in allogeneic bone marrow transplantation. Computer simulations show that, under a wide rage of dose‐outcome scenarios, the new method has high probabilities of making correct decisions and treats most patients at doses with desirable efficacy–toxicity trade‐offs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Simplex Method for Function Minimization
Nelder, J. A., & Mead, R. (1965) · The Computer Journal · doi:10.1093/comjnl/7.4.308 · Cited by 28,905
(2005) · Statistics for Biology and Health · doi:10.1007/0-387-27255-0_9 · Cited by 20,133
McCullagh, P., & Nelder, J. A. (1989) · doi:10.1007/978-1-4899-3242-6 · Cited by 16,836
Multivariate Models and Dependence Concepts.
Ringrose, T., & Joe, H. (1998) · Biometrics · doi:10.2307/2533875 · Cited by 3,403
Multivariate Models and Multivariate Dependence Concepts
Joe, H. (1997) · C&H/CRC Monographs on Statistics & Applied Probability · doi:10.1201/b13150 · Cited by 2,849
Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
O'Quigley, J., Pepe, M., & Fisher, L. (1990) · Biometrics · doi:10.2307/2531628 · Cited by 1,577
Glonek, G. F. V., & McCullagh, P. J. (1995) · Journal of the Royal Statistical Society Series B (Statistical Methodology) · doi:10.1111/j.2517-6161.1995.tb02046.x · Cited by 321
Thall, P. F., & Russell, K. E. (1998) · Biometrics · doi:10.2307/2534012 · Cited by 278
Self-citationSelecting Therapeutic Strategies Based on Efficacy and Death in Multicourse Clinical Trials
Thall, P. F., Sung, H., & Estey, E. H. (2002) · Journal of the American Statistical Association · doi:10.1198/016214502753479202 · Cited by 119
Self-citationApproaches for Optimal Sequential Decision Analysis in Clinical Trials
Carlin, B. P., Kadane, J. B., & Gelfand, A. E. (1998) · Biometrics · doi:10.2307/2533849 · Cited by 110
Cited by
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Liu, E., Marin, D., Banerjee, P., Macapinlac, H. A., Thompson, P., Basar, R., Nassif Kerbauy, L., Overman, B., Thall, P., Kaplan, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910607 · Cited by 2,217
Self-citationDose Escalation Methods in Phase I Cancer Clinical Trials
Le Tourneau, C., Lee, J. J., & Siu, L. L. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp079 · Cited by 867
Maki, R. G., Wathen, J. K., Patel, S. R., Priebat, D. A., Okuno, S. H., Samuels, B., Fanucchi, M., Harmon, D. C., Schuetze, S. M., Reinke, D., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.4117 · Cited by 742
Self-citationClinical development of new drug–radiotherapy combinations
on behalf of the NCRI CTRad Academia-Pharma Joint Working Group, Sharma, R. A., Plummer, R., Stock, J. K., Greenhalgh, T. A., Ataman, O., Kelly, S., Clay, R., Adams, R. A., Baird, R. D., et al. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.79 · Cited by 320
Adaptive Designs for Randomized Trials in Public Health
Brown, C. H., Ten Have, T. R., Jo, B., Dagne, G., Wyman, P. A., Muthén, B., & Gibbons, R. D. (2009) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.031308.100223 · Cited by 184
Metadata
- Authors
- Thall, P. F., & Cook, J. D.
- Venue
- Biometrics
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-08-27
- Volume
- 60
- Issue
- 3
- Pages
- 684-693
- ISSN
- 0006-341X (ISSN-L)
- 1541-0420
- OpenAlex
- W2129546350
- Cited by
- 522
- References
- 13
- FWCI
- 15.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dose‐Finding Based on Efficacy–Toxicity Trade‐Offs. https://app.cochat.ai/papers/10.1111/j.0006-341x.2004.00218.x
- The paper
- Thall, P. F., & Cook, J. D. (2004). Dose‐Finding Based on Efficacy–Toxicity Trade‐Offs. Biometrics. https://doi.org/10.1111/j.0006-341x.2004.00218.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.